Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)
Brief Summary: The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.


Options:
A: Arm Label: Axicabtagene Ciloleucel and Rituximab Combination; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Rituximab, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination
B: Arm Label: Treatment (T cell therapy); Type: EXPERIMENTAL; Interventions: Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes | Intervention Type: BIOLOGICAL; Name: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes; Assigned to Arm(s): Treatment (T cell therapy)
C: Arm Label: Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Pivotal Study): Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Pivotal Study): Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Safety Management Study): Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab | Arm Label: Phase 2 (Safety Management Study): Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab, Drug: Dexamethasone, Drug: High-dose methylprednisolone, Drug: Bendamustine, Drug: Rituximab | Arm Label: Phase 2 (Safety Management Study): Cohort 5; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Rituximab, Drug: Doxorubicin, Drug: Prednisone, Drug: Vincristine, Drug: Ifosfamide, Drug: Carboplatin, Drug: Etoposide, Drug: Gemcitabine, Drug: Oxaliplatin, Drug: Cisplatin | Arm Label: Phase 2 (Safety Management Study): Cohort 6; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab, Drug: Dexamethasone, Drug: High-dose methylprednisolone, Drug: Bendamustine, Drug: Rituximab, Drug: Methylprednisolone | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: High-dose methylprednisolone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Ifosfamide; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 6
D: Arm Label: Treatment (fludarabine, cyclophosphamide, CD19 T cell); Type: EXPERIMENTAL; Interventions: Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Drug: Cyclophosphamide, Drug: Fludarabine | Intervention Type: BIOLOGICAL; Name: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells; Assigned to Arm(s): Treatment (fludarabine, cyclophosphamide, CD19 T cell) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (fludarabine, cyclophosphamide, CD19 T cell) | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Treatment (fludarabine, cyclophosphamide, CD19 T cell)

Answer: A